Vancouver-based psychedelic drugs company Clearmind Medicine has filed another provisional patent application with the United States Patent and Trademark Office (USPTO). This is part of a broader collaboration with clinical-stage pharmaceutical company SciSparc to develop novel psychedelic-derived therapeutics for under-treated mental health conditions. 

The patent application aims to protect the combination of Clearmind's 5-Methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) for the treatment of depression. Clearmind has filed a total of nine patent applications with the USPTO, including the use of PEA and MEAI for the treatment of alcohol use disorder, cocaine addiction, obesity, and related metabolic disorders, as well as combinations of PEA with LSD, psilocybin, DMT, MDMA, ibogaine, and ketamine.

Clearmind Medicine (formerly Cyntar Ventures Inc.) is a psychedelic biotechnology company developing novel therapeutics based on MEAI, a psychoactive compound, to treat common conditions that are not currently effectively being addressed such as binge drinking and alcohol abuse. The company touts its intellectual property portfolio as a key strength, with 24 patents filed across the US, Europe, China, and India—nine of which have been granted.